A PSA test is a simple blood test that measures the level of prostate-specific antigen — a protein produced by prostate tissue. Elevated PSA can be caused by prostate cancer, but also by benign prostate enlargement, prostate inflammation, and other factors. PSA alone does not diagnose cancer; it identifies men who may benefit from further investigation.

What is a normal PSA level?

There is no single universal 'normal' PSA threshold. PSA levels rise naturally with age. A PSA above 3–4 ng/mL is commonly used as a threshold for further assessment in Australian practice. Age-specific reference ranges are sometimes applied. A raised PSA does not confirm cancer — most men with a raised PSA do not have prostate cancer.

Should all men get a PSA test?

No national screening programme exists for PSA testing in Australia. Most guidelines recommend an informed, individual discussion with a GP — typically from age 50 for average-risk men, or from 40–45 for those with a first-degree family history of prostate cancer or African ancestry. The decision should weigh potential benefits against the risk of false positives, unnecessary procedures, and overdiagnosis.

What happens if my PSA is elevated?

An elevated PSA does not mean you have prostate cancer. Your clinician will typically consider repeating the test, reviewing contributing factors such as prostatitis or benign prostatic hyperplasia, and discussing further investigation. MRI of the prostate is now commonly used before biopsy to improve targeting and reduce unnecessary procedures. If biopsy confirms cancer, the grade and extent guide treatment decisions.

What is overdiagnosis in prostate cancer?

Overdiagnosis occurs when a cancer is detected that would never have caused symptoms or shortened the person's life. Because many prostate cancers are slow-growing, some screen-detected cancers may fall into this category. Overdiagnosed cancers, when treated, expose men to side effects — including incontinence and erectile dysfunction — without benefit. Active surveillance is now the recommended approach for many low-risk cancers.

Can I choose not to have a PSA test?

Yes. PSA testing is a personal decision that you make with your clinician after understanding the trade-offs. If you decide not to be tested, that is a valid choice. Some men prefer to wait until symptoms arise. Shared decision-making means the decision belongs to you, informed by your risk profile, values, and the best available evidence.

PSA Screening: Benefits, Risks, and Shared Decision-Making

What Is PSA?

Prostate-specific antigen (PSA) is a protein produced by cells in the prostate gland — both normal cells and cancerous ones. A small amount of PSA normally enters the bloodstream. A blood test measures this level in nanograms per millilitre (ng/mL).

PSA is not specific to cancer. It can be elevated by a range of conditions:

Benign prostatic hyperplasia (BPH — non-cancerous prostate enlargement)
Prostatitis (prostate inflammation or infection)
Prostate cancer
Recent ejaculation (within 24–48 hours)
Vigorous exercise, particularly cycling
Urinary tract infection
Recent prostate biopsy or urinary instrumentation

Because of this, PSA is a marker for further investigation, not a diagnostic test. A raised PSA tells you something may need looking at — it does not tell you what that something is.

Key Points

PSA is a protein produced by the prostate; elevated levels may indicate cancer but also many benign conditions.
No national PSA screening programme exists in Australia; testing is based on informed individual discussion with a clinician.
Average-risk men are generally advised to consider the discussion from age 50; earlier for those with a family history of prostate cancer or African ancestry.
PSA screening can detect prostate cancer earlier — but also leads to overdiagnosis of cancers that would never cause harm.
Most men with a raised PSA do not have prostate cancer on biopsy.
Overtreatment of low-risk cancers causes significant side effects — incontinence and erectile dysfunction — without survival benefit.
Active surveillance — monitoring without immediate treatment — is now standard for many low-risk prostate cancers.
Shared decision-making, not universal recommendation, is the appropriate framework for PSA screening.

What the PSA Test Involves

The PSA test is a simple blood draw. No special preparation is required beyond avoiding vigorous exercise and sexual activity in the 24–48 hours beforehand. Results are typically available within a few days.

Factors that can falsely elevate PSA:

Recent ejaculation
Recent vigorous cycling or perineal pressure
Digital rectal examination (DRE) within 24–48 hours of the test
Prostatitis or urinary tract infection
Urinary catheterisation or recent prostate procedure

If any of these apply, the test may be deferred or the result interpreted with that context noted.

PSA Levels and Age

There is no universal cut-off for a “normal” PSA. PSA rises naturally as the prostate enlarges with age. Most Australian and international guidelines use 3.0–4.0 ng/mL as a common threshold for further investigation, though interpretation is always clinical and individualised.

Age	PSA Level Where Further Assessment Is Often Considered
Under 50	> 2.5 ng/mL
50–59	> 3.0 ng/mL
60–69	> 4.0 ng/mL
70 and over	Individualised; benefits of further investigation weigh less with advancing age

These figures are approximate guides, not diagnostic cut-offs. A PSA just below these levels does not exclude cancer; a PSA just above does not confirm it.

Benefits of PSA Screening

The European Randomised Study of Screening for Prostate Cancer (ERSPC) — one of the largest and longest-running trials — demonstrated that PSA screening can reduce prostate cancer mortality. At median follow-up of approximately 16 years, men in the screened group had around a 20% lower risk of dying from prostate cancer compared with the unscreened group.

Observational data from countries with widely adopted PSA testing have documented declines in late-stage prostate cancer diagnoses and prostate cancer deaths over time.

Specific potential benefits:

Detection of cancer while it is still localised to the prostate, when curative treatment is most effective
Greater treatment options for organ-confined disease
Earlier identification of men with aggressive cancer who benefit most from treatment
Potential reduction in prostate cancer-specific mortality for men who would otherwise progress to advanced disease

Risks and Limitations

PSA screening is more complex than most cancer screening tests because the balance between benefits and harms is narrower and more contested.

False Positives

A PSA above the threshold does not mean cancer is present. Most men with an elevated PSA do not have cancer on biopsy. False positives:

Cause significant anxiety
Lead to repeat blood tests and MRI
May result in prostate biopsy, which carries risks including infection, bleeding, and discomfort
In major screening trials, approximately 70–75% of men who underwent biopsy for elevated PSA did not have cancer

Overdiagnosis

Not all prostate cancers detected through PSA screening are clinically important. Autopsy studies have found prostate cancer in up to 40–60% of men who died of unrelated causes — meaning many prostate cancers never progress to cause symptoms or death.

Estimates suggest that 20–50% of screen-detected prostate cancers may represent overdiagnosis — cancers that would never have become symptomatic in the person’s lifetime. The range is wide because defining overdiagnosis precisely is methodologically difficult.

Overtreatment

When a cancer is detected, treatment has historically tended to follow — even for low-risk disease. Surgery (radical prostatectomy) and radiotherapy both carry meaningful side effect risks:

Urinary incontinence: affects 10–30% of men after radical surgery
Erectile dysfunction: affects 40–70% of men after surgery or radiotherapy
Bowel symptoms after pelvic radiotherapy
Anaesthetic and surgical complications

Active surveillance has substantially reduced overtreatment of low-risk cancers, but overtreatment remains a recognised harm of the screening pathway.

Placing the Numbers in Context

Using ERSPC trial data, for every 1,000 men screened over 13–16 years:

Approximately 1–2 prostate cancer deaths may be prevented
Approximately 100–200 men will have at least one false-positive PSA requiring further investigation
Approximately 5–10 men will be diagnosed with a cancer that would never have caused harm (overdiagnosis)
Approximately 2–5 men may experience lasting side effects from treatment of an overdiagnosed cancer

These figures explain why PSA screening is not straightforwardly beneficial or harmful — and why the decision genuinely belongs to the individual, not to population-wide guidance.

Understanding the Pathway After an Elevated PSA

A single elevated PSA does not immediately lead to biopsy. The modern pathway is more nuanced:

Repeat PSA — typically repeated after 4–6 weeks, avoiding confounding factors listed above
Clinical assessment — digital rectal examination, symptom review, assessment for prostatitis or BPH
Multiparametric MRI (mpMRI) — now commonly recommended before biopsy; identifies suspicious areas, reduces unnecessary biopsies, and improves targeting
PSA variants — free-to-total PSA ratio, PSA density (PSA adjusted for prostate volume), and PSA velocity may add information; higher free PSA proportion is associated with benign disease
Targeted biopsy — if MRI identifies a suspicious lesion, MRI-guided biopsy improves accuracy over systematic sampling alone
Grading — if cancer is found, the Gleason score (or ISUP grade group) classifies aggressiveness and guides management decisions

High-Risk Groups

Certain men face a substantially higher lifetime risk of prostate cancer and benefit from earlier, more proactive discussion about PSA testing:

Group	Risk Consideration
First-degree family history (father or brother diagnosed with prostate cancer)	Approximately 2–3× increased lifetime risk; discussion from age 45
Two or more affected first-degree relatives	Higher cumulative risk; discussion from age 40–45
African or African-Caribbean ancestry	Higher incidence and higher risk of aggressive disease; discussion from age 40–45
BRCA2 pathogenic variant carriers	Significantly elevated risk of aggressive prostate cancer; specialist review recommended
BRCA1 pathogenic variant carriers	Moderately elevated risk; individualised discussion warranted

Men in these groups benefit from a specific, proactive discussion with their GP or a urologist — not simply opportunistic testing without context.

Shared Decision-Making

PSA screening is one of medicine’s clearest examples of a test that requires genuine informed choice rather than a straightforward recommendation to act or to abstain.

A useful shared decision-making conversation covers:

What you are hoping to achieve:

Reassurance that cancer is not present?
Earlier detection to maximise treatment options if cancer is found?
A baseline PSA to monitor over time?

What you are weighing:

Comfort with uncertainty and follow-up procedures if PSA is elevated
Attitude to the possibility of finding a cancer that may never have caused harm
Awareness of treatment side effects if early-stage cancer is found and treated

A practical framework for the conversation:

Understand what a raised PSA result would trigger — repeat test, MRI, possible biopsy
Understand the likelihood that a raised result will not be cancer
Understand active surveillance as the standard approach for low-risk, localised disease
Make the decision in light of your values and risk tolerance, not just statistics alone

PSA screening is neither universally beneficial nor universally harmful. An informed, individual conversation with a GP who takes the time to explain the evidence is the appropriate standard — not a rushed blood test order, and not a dismissive refusal to discuss it.

Australian Context

Australia has no national organised PSA screening programme. PSA testing occurs opportunistically — initiated by the man, their GP, or as part of a broader men’s health check.

Key guidance in Australia:

The RACGP (Royal Australian College of General Practitioners) recommends that GPs neither routinely offer nor routinely discourage PSA testing. It supports an informed discussion for men aged 50–69 who wish to consider testing, and from age 45 for men with elevated family risk or African ancestry.
Cancer Council Australia does not recommend population-wide PSA screening. It supports informed decision-making, noting that the available evidence shows a modest reduction in prostate cancer mortality balanced against significant potential harms.
Cancer Australia endorses the shared decision-making model and does not recommend universal testing.

Medicare: A Medicare rebate applies to PSA testing in Australia. Testing is available through your GP as part of a standard consultation and pathology request.